Dinaciclib is a second-generation CDK inhibitor, which targets CDK1/2/5/9 and was evaluated for treating breast cancer, but undesirable side effects in part jeopardized its utility33, most likely due to poor specificity, inappropriate selectivity34 and potential off-target effects. This evidence concerns the gene CDK1 and breast carcinoma.